NCT04264403 (RDN-CKD) is a NA clinical trial of Renal denervation in Uncontrolled Hypertension, sponsored by University of Erlangen-Nürnberg Medical School.

Who is sponsoring NCT04264403?

NCT04264403 is sponsored by University of Erlangen-Nürnberg Medical School.

What drugs are being tested in NCT04264403?

Interventions in NCT04264403: Renal denervation.

What condition does NCT04264403 study?

NCT04264403 studies Uncontrolled Hypertension, Renal Denervation, Chronic Kidney Disease stage3.

Is NCT04264403 still recruiting?

NCT04264403 is currently status unknown. Last updated 21 December 2023.

Last reviewed 2023-12-21 · How we verify

NCT04264403: RDN-CKD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Renal Denervation in Chronic Kidney Disease - RDN-CKD Study

Status unknown NA Last updated 21 December 2023

What this trial tests

NA trial testing Renal denervation in Uncontrolled Hypertension in 44 participants. Status unknown.

Timeline

23 January 2020

Primary endpoint
23 December 2023

30 December 2023

Quick facts

Lead sponsor	University of Erlangen-Nürnberg Medical School
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	treatment
Enrollment	44
Start date	23 January 2020
Primary completion	23 December 2023
Estimated completion	30 December 2023
Sites	4 locations across Germany

Drugs / interventions tested

Renal denervation

Conditions studied

Uncontrolled Hypertension — all drugs for Uncontrolled Hypertension →
Renal Denervation — all drugs for Renal Denervation →
Chronic Kidney Disease stage3 — all drugs for Chronic Kidney Disease stage3 →

Sponsor

University of Erlangen-Nürnberg Medical School

Who can join

Adults 18 to 99, any sex, with Uncontrolled Hypertension or Renal Denervation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RDN-CKD Study is a prospective, randomized (1:1, central randomization), double-blind (unblinded interventionalist and blinded study team at each center), sham controlled, multicenter feasibility study. The purpose of the RDN-CKD Study is to demonstrate that renal denervation (RDN) effectively reduces 24-h ambulatory BP in 80 patients with chronic kidney disease (CKD) stage 3a or 3b.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Cardiorenal Syndrome: The Role of Neural Connections Between the Heart and the Kidneys.
Patel KP, Katsurada K, Zheng H. · · 2022 · cited 62× · PMID 35549375 · DOI 10.1161/circresaha.122.319989
Arterial hypertension - Clinical trials update 2021.
Al Ghorani H, Götzinger F, Böhm M, Mahfoud F. · · 2022 · cited 58× · PMID 34690044 · DOI 10.1016/j.numecd.2021.09.007
Hypertension and cardiomyopathy associated with chronic kidney disease: epidemiology, pathogenesis and treatment considerations.
Law JP, Pickup L, Pavlovic D, Townend JN, et al · · 2023 · cited 43× · PMID 36138105 · DOI 10.1038/s41371-022-00751-4
Advances in pathogenesis and treatment of essential hypertension.
Ma J, Chen X. · · 2022 · cited 29× · PMID 36312252 · DOI 10.3389/fcvm.2022.1003852
Renal denervation for resistant hypertension.
Pisano A, Iannone LF, Leo A, Russo E, et al · · 2021 · cited 14× · PMID 34806762 · DOI 10.1002/14651858.cd011499.pub3
Long-Term Safety and Antihypertensive Effects of Renal Denervation: Current Insights.
Reyes KRL, Rader F. · · 2023 · cited 5× · PMID 37701066 · DOI 10.2147/ibpc.s392410
New Aspects in the Management of Hypertension in Patients with Chronic Kidney Disease not on Renal Replacement Therapy.
Damianaki A, Polychronopoulou E, Wuerzner G, Burnier M. · · 2022 · cited 5× · PMID 34910287 · DOI 10.1007/s40292-021-00495-1
Catheter-based renal denervation in Chinese patients with chronic kidney disease and uncontrolled hypertension.
Liu S, Bian R, Qian Y, Liao H, et al · · 2023 · cited 4× · PMID 36478498 · DOI 10.1111/jch.14605

Verify or expand the search:

Other trials of Renal denervation

Trials testing the same drug.

NCT04535050 — DENEX Renal Denervation in Patients With Hypertension on no Antihypertensive Medications · NA · unknown
NCT05818813 — The Long-term Safety and Effect of Renal Denervation · terminated
NCT04314557 — Renal Arterial Denervation in Sympathetic Dysautonomia · completed
NCT04248530 — DENEX Renal Denervation in Patients With Uncontrolled Hypertension: Safety Study · NA · completed

Other recruiting trials for Uncontrolled Hypertension

Currently open trials in the same condition.

NCT07005050 — Renal Pelvic Denervation Pilot Trial · NA · recruiting
NCT06610448 — Wearable Evaluation of Ambulatory Readings for Blood Pressure · NA · recruiting
NCT06926855 — Community Health Workers Reduce Social Barriers That Affect the Health of Patients With High Blood Pressure and Diabetes · NA · active not recruiting
NCT06344104 — A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or Mo · Phase 3 · active not recruiting
NCT06938633 — Addressing Medication Non-adherence in Patients With Poorly Controlled Hypertension Using Urine Mass Spectrometry · NA · recruiting

Other University of Erlangen-Nürnberg Medical School trials

Trials by the same sponsor.

NCT06969820 — Establishment and Evaluation of Standardized Clinical, Biological and Imaging Parameters to Assess the Response of LDRT · not yet recruiting
NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
NCT07352540 — Single vs Triple Hyaluronic Acid in Knee Osteoarthritis · Phase 2, PHASE3 · not yet recruiting
NCT07313878 — Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Micros · NA · recruiting
NCT07121985 — Multispectral Optoacoustic Imaging for the Detection of Inflammation and Damage of Peripheral Nerves in Guillain-Barré S · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04264403 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Erlangen-Nürnberg Medical School
Last refreshed: 21 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04264403.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing